Jennifer Meeuwsen
Executive Vice President, EVERSANA COMPLETE Commercialization
Expertise:
Jennifer is the Executive Vice President of Complete Commercialization at EVERSANA, a leading provider of commercialization services to the life sciences industry. Her robust background includes more than two decades of market access strategies and commercialization across the life sciences and biotech industries.
Over her career, she has played a pivotal role in helping pharmaceutical companies successfully launch and sustain their products in the market. Her expertise includes amplifying unmet needs and highlighting value propositions to stakeholders, ensuring that new medications achieve their full potential. At EVERSANA, she oversees the company’s COMPLETE Commercialization solution, helping emerging pharmaceutical and biotech companies leverage the full suite of EVERSANA services to bring a product to market.
Prior to EVERSANA, she held senior commercialization roles at several biotech companies, including Integra Connect, Decipher Biosciences and Myriad Genetics. She began her career in business development and marketing roles in the pharmaceutical industry.
Jennifer holds a bachelor’s degree in marketing and international business from Western Michigan University.
Articles by Jennifer Meeuwsen
Beyond Theory: Integrated Commercialization Model Proves Valuable in Launch Success
Unlock the Future of Drug Commercialization Discover the Proven Strategies Behind Successful Drug Launches Are you ready to revolutionize your drug commercialization approach? Download our exclusive whitepaper, “Beyond Theory: Integrated Commercialization Model Proves Valuable in Launch Success,” and gain insights from industry leaders at EVERSANA. What You’ll Learn: Comprehensive Outsourcing Strategies: Explore how EVERSANA COMPLETE Commercialization® offers both end-to-end and flexible, just-in-time outsourcing solutions tailored to your needs. Case Studies of Success: Learn from real-world examples where our integrated model has driven efficiency, cost savings, and improved patient outcomes. Agility in Action: Understand how our model adapts to evolving market conditions, helping you navigate regulatory hurdles and optimize your launch strategy. Expert Insights: Benefit from the […]